Prime Medicine, Inc. Common Stock (PRME) - Total Liabilities
Based on the latest financial reports, Prime Medicine, Inc. Common Stock (PRME) has total liabilities worth $223.19 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PRME cash flow metrics to assess how effectively this company generates cash.
Prime Medicine, Inc. Common Stock - Total Liabilities Trend (2019–2024)
This chart illustrates how Prime Medicine, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check PRME asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Prime Medicine, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Prime Medicine, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Regal Partners Ltd
AU:RPL
|
Australia | AU$164.10 Million |
|
Uxin Ltd
NASDAQ:UXIN
|
USA | $15.20 Billion |
|
Guizhou Taiyong Changzheng Technology Co Ltd Class A
SHE:002927
|
China | CN¥603.03 Million |
|
D&O Home Collection Co Ltd
SHE:002798
|
China | CN¥3.57 Billion |
|
Haier Smart Home Co Ltd
F:690D
|
Germany | €169.82 Billion |
|
Oeneo SA
PA:SBT
|
France | €193.53 Million |
|
Tianjin LVYIN Landscape and Ecology Construction Co Ltd
SHE:002887
|
China | CN¥1.58 Billion |
|
Forward Air Corporation
NASDAQ:FWRD
|
USA | $2.58 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Prime Medicine, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Prime Medicine, Inc. Common Stock stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prime Medicine, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prime Medicine, Inc. Common Stock (2019–2024)
The table below shows the annual total liabilities of Prime Medicine, Inc. Common Stock from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $144.36 Million | +137.51% |
| 2023-12-31 | $60.78 Million | +38.00% |
| 2022-12-31 | $44.04 Million | -29.30% |
| 2021-12-31 | $62.30 Million | +192.35% |
| 2020-12-31 | $21.31 Million | +191.58% |
| 2019-12-31 | $7.31 Million | -- |
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that… Read more